Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05891275 · ClinicalTrials.gov registry record
Patients With Geographic Atrophy and Their Patient Journey in the United States (US)
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 68,563
- Enrollment target
NCT05891275 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 68,563 participants.
The verdict
NCT05891275 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 68,563 participants
- Enrollment target
Study Summary
To quantify and describe patients with a Geographic Atrophy (GA) diagnosis in at least one eye, and the progression to neovascular Age-Related Macular Degeneration (including how many receive Anti-VEGF), or to GA (in the fellow eye only).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68,563 participants |
| Start Date | 2023-05-31 |
| Est. Completion | 2023-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05891275
The ClinicalTrials.gov registry entry for NCT05891275 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 68,563 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05891275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05891275 about?
NCT05891275 is a clinical study titled "Patients With Geographic Atrophy and Their Patient Journey in the United States (US)". To quantify and describe patients with a Geographic Atrophy (GA) diagnosis in at least one eye, and the progression to neovascular Age-Related Macular Degeneration (including how many receive Anti-VEGF), or to GA (in the fellow eye only).
What is the current status of trial NCT05891275?
This trial is currently completed. The enrollment target is 68,563 participants. The study started on 2023-05-31. Estimated completion is 2023-12-01.
Who is sponsoring clinical trial NCT05891275?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.